Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
New breast cancer research from P.A. Cassier and co-researchers described
July 3rd, 2008
According to recent research published in the journal Breast Cancer Research and Treatment, " In first-line metastatic breast cancer, both paclitaxel (P)-doxorubicin (A) and docetaxel (D)doxorubicin (A) combinations have shown superiority over treatments without taxane. The aim of this study was to compare the two combinations." "Patients and methods Chemotherapy-naive (except for adjuvant therapy) metastatic breast cancer patients were randomly assigned to intravenous AD (arm D) or AP (arm P) every 3 weeks for a maximum of four cycles, then four cycles of single agent docetaxel (arm D) or paclitaxel (arm P). Primary endpoint was overall quality of life (QoL)...
Source: Women's Health Weekly (2008-07-03)
|
